Related references
Note: Only part of the references are listed.Pseudoprogression of extramedullary disease in relapsed acute lymphoblastic leukemia after CAR T-cell therapy
Jie Huang et al.
IMMUNOTHERAPY (2021)
Prognostic Value of Serum Soluble Programmed Death-Ligand 1 and Dynamics During Chemotherapy in Advanced Gastric Cancer Patients
Woochan Park et al.
CANCER RESEARCH AND TREATMENT (2021)
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100
Markus Moehler et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811
Hyun Cheol Chung et al.
FUTURE ONCOLOGY (2021)
Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials
F. Pietrantonio et al.
ESMO OPEN (2021)
PD-L1 expression in gastroesophageal dysplastic lesions
Matteo Fassan et al.
VIRCHOWS ARCHIV (2020)
Significant function and research progress of biomarkers in gastric cancer (Review)
Dong Mei Ye et al.
ONCOLOGY LETTERS (2020)
An open-label phase II study of lenvatinib plus pembrolizumab in patients with advanced gastric cancer (EPOC1706).
Akihito Kawazoe et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Expression of programmed death ligand 1 (PD-L1) is associated with metastasis and differentiation in gastric cancer
Peng-xing He et al.
LIFE SCIENCES (2020)
High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features
Xiaoqiao Liu et al.
PATHOLOGY RESEARCH AND PRACTICE (2020)
Nivolumab in Heavily Pretreated Metastatic Gastric Cancer Patients: Real-Life Data from a Western Population
Angelica Petrillo et al.
ONCOTARGETS AND THERAPY (2020)
Pembrolizumab versus paclitaxel for previously treated patients with PD-L1–positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.
Charles S. Fuchs et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
Yelena Y. Janjigian et al.
LANCET ONCOLOGY (2020)
MSI and EBV Positive Gastric Cancer's Subgroups and Their Link with Novel Immunotherapy
Maria Grazia Rodriquenz et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers
Raghav Sundar et al.
FRONTIERS IN ONCOLOGY (2020)
KEYNOTE-859: A randomized, double-blind, placebo-controlled phase 3 trial of first-line pembrolizumab plus chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma
J. Tabernero et al.
ANNALS OF ONCOLOGY (2020)
The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target
V Gambardella et al.
CANCER TREATMENT REVIEWS (2020)
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
Florent Peyraud et al.
CANCERS (2020)
Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study
N. Boku et al.
ANNALS OF ONCOLOGY (2020)
Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study
R. J. Kelly et al.
ANNALS OF ONCOLOGY (2020)
Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study
M. Moehler et al.
ANNALS OF ONCOLOGY (2020)
The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee
Lynette Sholl et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial
Daniel V. T. Catenacci et al.
LANCET ONCOLOGY (2020)
Hereditary diffuse gastric cancer: updated clinical practice guidelines
Vanessa R Blair et al.
LANCET ONCOLOGY (2020)
The 5-Ws of immunotherapy in head and neck cancer
Andrea Botticelli et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)
A decade of immune-checkpoint inhibitors in cancer therapy
Caroline Robert
NATURE COMMUNICATIONS (2020)
The Crosstalk between Microbiome and Immune Response in Gastric Cancer
Rihab Nasr et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
Jessica Wagner et al.
MOLECULAR THERAPY (2020)
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Kohei Shitara et al.
JAMA ONCOLOGY (2020)
Multimodality Treatment in Metastatic Gastric Cancer: From Past to Next Future
Alessandro Parisi et al.
CANCERS (2020)
Mismatch Repair System Genomic Scars in Gastroesophageal Cancers: Biology and Clinical Testing
Gianluca Lopez et al.
GASTROINTESTINAL DISORDERS (2020)
Genetic profiling for diffuse type and genomically stable subtypes in gastric cancer
Yiwei Ling et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2020)
Biomarkers for Precision Treatment in Gastric Cancer
Angelica Petrillo et al.
VISCERAL MEDICINE (2020)
Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: a meta-analysis and experimental validation
Nana Zhang et al.
ARCHIVES OF MEDICAL SCIENCE (2020)
Gastrointestinal cancers: current biomarkers in esophageal and gastric adenocarcinoma
Purabi Dhakras et al.
TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
Leigh Marcus et al.
CLINICAL CANCER RESEARCH (2019)
KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer
Yung-Jue Bang et al.
FUTURE ONCOLOGY (2019)
Phase I/II study of ramucirumab plus nivolumab in patients in second-line treatment for advanced gastric adenocarcinoma (NivoRam study).
Hiroki Hara et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial
Sherene Loi et al.
LANCET ONCOLOGY (2019)
Aberrations in DNA repair pathways in cancer and therapeutic significances
Akira Motegi et al.
SEMINARS IN CANCER BIOLOGY (2019)
Determination of Mismatch Repair Status in Human Cancer and Its Clinical Significance: Does One Size Fit All?
Chiara Corti et al.
ADVANCES IN ANATOMIC PATHOLOGY (2019)
ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
C. Luchini et al.
ANNALS OF ONCOLOGY (2019)
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
Salah-Eddin Al-Batran et al.
LANCET (2019)
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study
Alessandro Parisi et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
Pengfei Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Tumor Vasculatures: A New Target for Cancer Immunotherapy
Zhigang Liu et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2019)
GLOBAL REGULATORY CHALLENGES OF CAR T-CELL THERAPIES: APPROVAL, PRICING, AND ACCESS
Z. Ou
VALUE IN HEALTH (2019)
Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors
Kiyohiro Ando et al.
ANTICANCER RESEARCH (2019)
Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer
Filippo Pietrantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Immuno-oncology drug development goes global
Jia Xin Yu et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Epstein-Barr Virus Infection Promotes Epithelial Cell Growth by Attenuating Differentiation-Dependent Exit from the Cell Cycle
Mark R. Eichelberg et al.
MBIO (2019)
Use of immunotherapy in the treatment of gastric cancer
Luhong Yang et al.
ONCOLOGY LETTERS (2019)
Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers
Fabio Pagni et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load
Hyunchul Jung et al.
NATURE COMMUNICATIONS (2019)
Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression
Tsunehiko Shigemori et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Cancer Neoantigens
Ton N. Schumacher et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 37, 2019 (2019)
Multi-Modality Treatment for Patients With Metastatic Gastric Cancer: A Real-World Study in China
Lin Zhao et al.
FRONTIERS IN ONCOLOGY (2019)
Molecular insight of regorafenib treatment for colorectal cancer
Hiroyuki Arai et al.
CANCER TREATMENT REVIEWS (2019)
MMR protein immunohistochemistry and microsatellite instability in gastric cancers
Junhun Cho et al.
PATHOLOGY (2019)
Harnessing DNA Double-Strand Break Repair for Cancer Treatment
Anika Trenner et al.
FRONTIERS IN ONCOLOGY (2019)
Increased Stromal Infiltrating Lymphocytes are Associated with Circulating Tumor Cells and Metastatic Relapse in Breast Cancer Patients After Neoadjuvant Chemotherapy
Jiawei Liu et al.
CANCER MANAGEMENT AND RESEARCH (2019)
A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer
Raghav Sundar et al.
BMC CANCER (2018)
Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices
A. Scott Paulson et al.
GASTRIC CANCER (2018)
Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward
Jian Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara et al.
LANCET (2018)
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
Seung Tae Kim et al.
NATURE MEDICINE (2018)
The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies
Laurence Zitvogel et al.
SCIENCE (2018)
Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study
Maria Di Bartolomeo et al.
TARGETED ONCOLOGY (2018)
Biomarkers of gastric cancer: Current topics and future perspective
Tasuku Matsuoka et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Advances in immuno-oncology biomarkers for gastroesophageal cancer: programmed death ligand 1, microsatellite instability, and beyond
Emily M. Lin et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs et al.
JAMA ONCOLOGY (2018)
Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
Y. -J. Bang et al.
ANNALS OF ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Soluble LAG3 acts as a potential prognostic marker of gastric cancer and its positive correlation with CD8+T cell frequency and secretion of IL-12 and INF-γ in peripheral blood
Na Li et al.
CANCER BIOMARKERS (2018)
Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches
Margherita Ratti et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2018)
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
Yelena Y. Janjigian et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: A systematic review and meta-analysis
Jung Soo Lee et al.
MEDICINE (2018)
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial
Kohei Shitara et al.
LANCET ONCOLOGY (2018)
Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer
K. Polom et al.
BRITISH JOURNAL OF SURGERY (2018)
Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy
Riccardo Giampieri et al.
GASTRIC CANCER (2017)
Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia
Mika Shapiro et al.
HAEMATOLOGICA (2017)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET (2017)
Tumour-associated macrophages as treatment targets in oncology
Alberto Mantovani et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Predictive relevance of PD-L1 expression with pre-existing TILs in gastric cancer
Xiaoli Ju et al.
ONCOTARGET (2017)
Hypermutation and microsatellite instability in gastrointestinal cancers
Kizuki Yuza et al.
ONCOTARGET (2017)
Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia
Mika Shapiro et al.
HAEMATOLOGICA (2017)
Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis
Wouter Hendrickx et al.
ONCOIMMUNOLOGY (2017)
Correlation of benefit from immune checkpoint inhibitors with next gen sequencing (NGS) profiles in esophagogastric cancer (EGC) patients.
Geoffrey Yuyat Ku et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors
Shona Hendry et al.
ADVANCES IN ANATOMIC PATHOLOGY (2017)
Modest overall survival improvements from 1998 to 2009 in metastatic gastric cancer patients: a population-based SEER analysis
Sabrina M. Ebinger et al.
GASTRIC CANCER (2016)
CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
Elizabeth I. Buchbinder et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability
Changqing Ma et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2016)
Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy
J. M. Pitt et al.
ANNALS OF ONCOLOGY (2016)
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
E. C. Smyth et al.
ANNALS OF ONCOLOGY (2016)
Chimeric antigen receptor T cell therapy: 25 years in the making
Saar Gill et al.
BLOOD REVIEWS (2016)
Distinct Subtypes of Gastric Cancer Defined by Molecular Characterization Include Novel Mutational Signatures with Prognostic Capability
Xiangchun Li et al.
CANCER RESEARCH (2016)
Current Perspectives on Gastric Cancer
Juan M. Marques-Lespier et al.
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2016)
Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer
Naoki Takahashi et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2016)
Lauren classification and individualized chemotherapy in gastric cancer (Review)
Junli Ma et al.
ONCOLOGY LETTERS (2016)
Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome
Linan Wang et al.
ONCOIMMUNOLOGY (2016)
Cancer gene therapy with T cell receptors and chimeric antigen receptors
Hans J. Stauss et al.
CURRENT OPINION IN PHARMACOLOGY (2015)
ErbB-targeted CAR T-cell immunotherapy of cancer
Lynsey M. Whilding et al.
IMMUNOTHERAPY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Tracking the Genomic Evolution of Esophageal Adenocarcinoma through Neoadjuvant Chemotherapy
Nirupa Murugaesu et al.
CANCER DISCOVERY (2015)
Vascular Endothelial Growth Factor A Inhibition in Gastric Cancer
Do Joong Park et al.
GASTRIC CANCER (2015)
Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial
Ryan D. Guest et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke et al.
LANCET ONCOLOGY (2014)
Comprehensive molecular characterization of gastric adenocarcinoma
Adam J. Bass et al.
NATURE (2014)
Pathohistological classification systems in gastric cancer: Diagnostic relevance and prognostic value
Felix Berlth et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Members of the EpCAM signalling pathway are expressed in gastric cancer tissue and are correlated with patient prognosis
V. S. Warneke et al.
BRITISH JOURNAL OF CANCER (2013)
Microsatellite Instability Status in Gastric Cancer: A Reappraisal of Its Clinical Significance and Relationship with Mucin Phenotypes
Joo-Yeun Kim et al.
KOREAN JOURNAL OF PATHOLOGY (2013)
Roles of LAG3 and EGR2 in regulatory T cells
Tomohisa Okamura et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer
Toru Masuzawa et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines
Yongjing Chen et al.
CYTOKINE (2011)
The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
SaeGwang Park et al.
CANCER CELL (2010)
EBV-infection in cardiac and non-cardiac gastric adenocarcinomas is associated with promoter methylation of p16, p14 and APC, but not hMLH1
Helene Geddert et al.
ANALYTICAL CELLULAR PATHOLOGY (2010)
G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy
A. D. Gilliam et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: The GC4 study
JA Ajani et al.
CANCER (2006)
Current developments in cancer vaccines and cellular immunotherapy
A Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
The prognostic significance of gastric juice CA 19-9 and CEA levels in gastric carcinoma patients
N Duraker et al.
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY (2002)
Share Paper
